Toxicity Testing, Inhalation

Baran, K.P.

doi:10.1016/b978-0-12-386454-3.00952-0

Cited by 1 publication

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Instillation is not a physiological route for humans [ 112 ]. There are several advantages in that only a small amount of therapeutic is needed, and the doses can be precisely administered to the respiratory tract [ 113 ]. That said, intratracheal instillation may lead to inconsistent deposition, largely in the upper airways (heterogenous distribution), and medication tends to rely on a gravitational and regular mucociliary beat to disperse throughout the lung, thus leading to inconsistent deposition patterns [ 113 ].…”

Section: Route Of Administrationmentioning

confidence: 99%

“…There are several advantages in that only a small amount of therapeutic is needed, and the doses can be precisely administered to the respiratory tract [ 113 ]. That said, intratracheal instillation may lead to inconsistent deposition, largely in the upper airways (heterogenous distribution), and medication tends to rely on a gravitational and regular mucociliary beat to disperse throughout the lung, thus leading to inconsistent deposition patterns [ 113 ]. Xisto’s comparative study in 2011 hypothesized that intratracheal administration was more effective than intravenous administration when modulating the inflammatory and fibrogenic “process” [ 114 ].…”

Section: Route Of Administrationmentioning

confidence: 99%

See 1 more Smart Citation

State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery

Brave

MacLoughlin

2020

IJMS

View full text Add to dashboard Cite

Respiratory and pulmonary diseases are among the leading causes of death globally. Despite tremendous advancements, there are no effective pharmacological therapies capable of curing diseases such as COPD (chronic obstructive pulmonary disease), ARDS (acute respiratory distress syndrome), and COVID-19. Novel and innovative therapies such as advanced therapy medicinal products (ATMPs) are still in early development. However, they have exhibited significant potential preclinically and clinically. There are several longitudinal studies published, primarily focusing on the use of cell therapies for respiratory diseases due to their anti-inflammatory and reparative properties, thereby hinting that they have the capability of reducing mortality and improving the quality of life for patients. The primary objective of this paper is to set out a state of the art review on the use of aerosolized MSCs and their potential to treat these incurable diseases. This review will examine selected respiratory and pulmonary diseases, present an overview of the therapeutic potential of cell therapy and finally provide insight into potential routes of administration, with a focus on aerosol-mediated ATMP delivery.

show abstract

Section: Route Of Administrationmentioning

confidence: 99%